Visiongain Publishes Zika Virus Testing Market Forecast 2020-2030

26 September 2020
Pharma

Zika Virus Testing Market Forecast 2020-2030: Forecasts and Analysis By Diagnostic Test Type, By End User, and Geography, with Profiles of Leading Companies, with Profiles of Leading Companies report provides impartial Zika Virus Testing sector analysis.

According to the report published by Visiongain, the Zika Virus Testing market was valued at approximately USD xx million in 2019 and is expected to grow at a CAGR of around xx% between 2020 and 2030. The virus Zika is a flavivirus which has Zika virus disease caused by infection. The infected Aedes species mosquitoes primarily transmit the virus. Nevertheless, Zika virus can be passed on to his or her sexual partner by an infected man. Although Zika virus infection typically is asymptomatic or induces moderate disease, a risk of Zika virus and developmental microcephaly as well as other serious brain defects occur. Molecular and serological testing are included in diagnostic tests to determine Zika virus infection. This policy outlines the requirements of the medical need for diagnostic tests.

Zika Virus Testing Market is witnessing Growth due to factors such as
Zika virus, more frequently spread by Ae, is mainly the bites of contaminated Aedes mosquitoes. Aegypti and perhaps Ae. Ae. Mosquitoes of albopictus. 3 Zika virus has been documented for sexually transmitted from males to their sexual partners, from 4 to females to male sexual partners. 14 The hazard assessment of Zika virus is actually of unknown interest, unless the two spouses become symptomatic and a person decides to marry, because the virus has little understanding for male genitourinary tract loss.

One of the major trends in increasing market growth is the participation of international organisations, such as UNICEF, and national governments in low-income developed countries. Moreover, a 2016 outbreak of Zika virus (ZIKV) has contributed to enormous traction of the market. In Brazil, between 2015 and 2016, there were about 1 950 cases of microcephaly in this region. A threat to public health was declared to be zika virus in October 2016, after a correlation was found between ZIKV and neurological birth defects in Brazil. This link between microcephaly in newborn babies with ZIKV has increased surveillance efforts and a demand for diagnostics since the end of the 2016 Zika epidemic. CDC reports that 5,264 individuals have been Zika infected in the U.S., where more than 1,700 pregnant women have been identified with Zika positive and 58 babies have born with birth defects.

A large part of the disease-related transmission in certain countries contributed to Zika virus in 2016. In the United States, 4,830 Zika-related cases have been reported, representing 94.0% of the overall cases for 2016. In addition to symptomatic cases testing to prevent transmission of diseases that drive the demand for ZIKV diagnostics, blood testing for Zika infection has therefore also been incorporated. In the US and Singapore, blood donations to Zika virus infections will primarily be diagnosed.

Organizations like the WHO, the PAHO and UNICEF have launched social approaches to Zika as a global impact. Such methods vary from therapeutic structures to stocks for clinical care. In addition to supporting preventive and prophylactic Zika virus studies, the organizations focus on potential emergency diagnostics, which help the market's expansion.

Development of POC diagnostics which produce fast results can shape the market's future. UNICEF and PAHO are proposing early buy-out agreements (APC) to facilitate fast diagnostics for the prevention of zika viruses. These APCs cover endemic areas of ZIKV that threaten potential outbreaks and require fast diagnostic testing. UNICEF has sealed contracts for the supply of their valid 2019 Zika detection tests by Chembio Diagnostics Systems, Inc. and SD Biosensors, Inc.

In 2016, NAAT and serological testing were both diagnose-test types, and held nearly equal market shares, with both tests performed on most subjects to confirm ZIKV infection during the epidemic. The NAAT segment, however, has a small margin as it is more widely available and can be used with economic efficiency for large-scale surveillance. With the conclusion of the outbreak at the start of 2017, both severe and late stage ZIKV disease began to take priority over NAAT. Furthermore, new fast serologic identification diagnostics also provide shorter turnaround times and differentiated Zika diagnosis from other flavi viruses.

Regional Market Analysis
The zika virus diagnostics sector is listed in the USA from a national point of view. States and territories, Europe, Latin America and Africa, Asia and the Pacific. In 2019, the USA was dominated by states and territories. The United States has since its outbreak, by collaboration with organizations such as the CDC, the WHO and the PAHO, developed a national response framework to prevent viral propagation across the country. Another major element in the region's market growth was the national mandate passed in 2015 requiring all donated blood to be subjected to individual Zika virus donor-NAAT screenings. The second most extensive market in Latin America in 2019 accounted for more than 45% of ZIKV infections worldwide. The existence of vectors, Aedes aegypti mosquitoes, also increases the likelihood of virus development in the area. In Brazil, during four months, October 2015 to January 2016, over 4,000 suspected cases of microcephaly in newborns were recorded. The Brazil's National Development Bank (BNDES), reported in March 2016 that financing worth USD 136.6 million will also work in favor of regional markets in order to combat vector-borne diseases, including ZIKV.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

Read

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Visiongain Publishes Biological Imaging Reagents Market Report 2021-2031

Increasing prevalence of cardiovascular diseases is increasing demand of biological imaging reagents for the diagnosis and treatment of cardiovascular diseases due to this reason increasing prevalence of cardiovascular diseases is acting as a driver for biological imaging reagent market.

13 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever